|

Emavusertib Clinical Trials

6 actively recruiting trials across 6 locations

▼ -1 trial since May 2026

Also known as: AU 4948, AU-4948, CA 4948, CA-4948, CA4948 +2 more

Pipeline

Phase 1: 3Phase 2: 2Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)3
  • Curis, Inc.2
  • Washington University School of Medicine1

Indications

  • Cancer6
  • Metastatic Biliary Tract Carcinoma1
  • Unresectable Colorectal Adenocarcinoma1
  • Refractory Hematologic Malignancy1
  • Metastatic Biliary Tract Cancer1

Birmingham, Alabama1 trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Phoenix, Arizona1 trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

St. Joseph's Hospital and Medical Center

Phase 1/2

Duarte, California1 trial

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

City of Hope Comprehensive Cancer Center

Phase 1

Gainesville, Florida1 trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

UF Health Cancer Institute - Gainesville

Phase 1

Miami Beach, Florida1 trial

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Mt Sinai Comprehensive Cancer Center

Phase 2

St Louis, Missouri1 trial

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Washington University School of Medicine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.